B
Bertram Pitt
Researcher at University of Michigan
Publications - 834
Citations - 88351
Bertram Pitt is an academic researcher from University of Michigan. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 107, co-authored 754 publications receiving 78458 citations. Previous affiliations of Bertram Pitt include Rutgers University & Tufts Medical Center.
Papers
More filters
Journal ArticleDOI
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
George L. Bakris,Rajiv Agarwal,Stefan D. Anker,Bertram Pitt,Luis M. Ruilope,Christina Nowack,Peter Kolkhof,Anna C. Ferreira,Patrick Schloemer,Gerasimos Filippatos +9 more
TL;DR: The FIDELIO-DKD trial will determine whether an optimally treated cohort of T2D patients with CKD at high risk of renal and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
Journal ArticleDOI
Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.
Bertram Pitt,Philip A. Poole-Wilson,Robert Segal,Felipe Martinez,Kenneth Dickstein,A. John Camm,Marvin A. Konstam,Günter A.J. Riegger,George Klinger,James D. Neaton,Divakar Sharma,Balasamy Thiyagarajan +11 more
TL;DR: The ELITE II study will further define the role of losartan in the treatment of patients with symptomatic heart failure relative to the angiotensin-converting enzyme inhibitor captopril, an agent from a class currently considered standard treatment for this disease.
Journal ArticleDOI
Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: Improved timing, thrombolytic efficacy and ventricular function
Eric J. Topol,Eric R. Bates,Joseph A. Walton,Gregory Baumann,Stanley Wolfe,John Maino,Leonard Bayer,Laura Gorman,Eva M. Kline,William W. O'Neill,Bertram Pitt +10 more
TL;DR: As an investigational fibrinolytic agent for acute myocardial infarction, intravenous recombinant tissue-type plasminogen activator (rt-PA) has been administered primarily in tertiary care and university centers and the value of early initiation of such therapy was determined.
Journal ArticleDOI
Value of percutaneous transluminal coronary angioplasty after unsuccessful intravenous streptokinase therapy in acute myocardial infarction
Anthony Fung,Peter Lai,Eric J. Topol,Eric R. Bates,Patrick D.V. Bourdillon,Joseph A. Walton,G.B.John Mancini,Theresa Kryski,Bertram Pitt,William W. O'Neill +9 more
TL;DR: Sequential intravenous streptokinase and emergency PTCA is efficacious in achieving coronary reperfusion and in improving both global and regional left ventricular function.
Journal ArticleDOI
Cyclooxygenase-2 Inhibition and Cardiovascular Events
TL;DR: Introduction of selective cyclooxygenase (COX)-2 inhibitors held a promise of improved treatment of arthritis without the gastrointestinal effects associated with aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), which effect both COX-1 andCOX-2 activity.